(Q45807714)

16 December 2017

title

Movement disorder in ataxia-telangiectasia: treatment with amantadine sulfate (English)

1 reference

16 December 2017

main subject

amantadine sulfate

1 reference

ChEBI release 2020-05-28

Andreea Nissenkorn

1

1 reference

16 December 2017

Sharon Hassin-Baer

2

1 reference

16 December 2017

Sheera F Lerman

3

1 reference

16 December 2017

Yonit Banet Levi

4

1 reference

16 December 2017

Michal Tzadok

5

1 reference

16 December 2017

Bruria Ben-Zeev

6

1 reference

16 December 2017

publication date

1 May 2012

1 reference

16 December 2017

Journal of Child Neurology

published in

1 reference

16 December 2017

volume

28

1 reference

16 December 2017

issue

2

1 reference

16 December 2017

page(s)

155-160

1 reference

16 December 2017

Current and potential therapeutic strategies for the treatment of ataxia-telangiectasia.

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0883073812441999

Ataxia-telangiectasia: diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073812441999

Neurologic presentation in children with ataxia-telangiectasia: is small head circumference a hallmark of the disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073812441999

Steroid-induced improvement of neurological signs in ataxia-telangiectasia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073812441999

Efficacy of very-low-dose betamethasone on neurological symptoms in ataxia-telangiectasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073812441999

In ataxia-teleangiectasia betamethasone response is inversely correlated to cerebellar atrophy and directly to antioxidative capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073812441999

Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073812441999

Amantadine hydrochloride treatment in heredodegenerative ataxias: a double blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073812441999

Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073812441999

Amantadine in the akinetic-rigid variant of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073812441999

Dopamine agonist therapy in low-response children following traumatic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073812441999

Amantadine to improve neurorecovery in traumatic brain injury-associated diffuse axonal injury: a pilot double-blind randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073812441999

Open-label amantadine in children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073812441999

Amantadine inhibits NMDA receptors by accelerating channel closure during channel block.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073812441999

Unified Parkinson's Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073812441999

A single ataxia telangiectasia gene with a product similar to PI-3 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073812441999

ATM activation by oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073812441999

Cerebellar network plasticity: from genes to fast oscillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073812441999

Pharmacological treatments of cerebellar ataxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073812441999

Dopamine D2 receptor signaling modulates mutant ataxin-1 S776 phosphorylation and aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073812441999

Nigrostriatal involvement in ataxia with oculomotor apraxia type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073812441999

Neostriatal glutamatergic system is involved in the pathogenesis of picrotoxin-induced choreomyoclonic hyperkinesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073812441999

d-Cycloserine for the treatment of ataxia in spinocerebellar degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073812441999

An open trial of amantadine and buspirone for cerebellar ataxia: a disappointment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073812441999

Quantitative neurologic assessment of ataxia-telangiectasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073812441999

21 January 2018

Identifiers

DOI

10.1177/0883073812441999

1 reference

16 December 2017

release_2zx6j67srra7zbexho2dcvagou

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2zx6j67srra7zbexho2dcvagou

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

16 December 2017